Significant public attention has recently been focused on the development of new anti-influenza vaccines that provide protection against a broad spectrum of viral strains. One proposed strategy is to utilize conserved viral protein, M2. Clinical trials of M2-containing influenza vaccines were recently initiated by US and European companies.
Full Article
Nick
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment